For any company entering the immunotherapy field, manufacturing and logistics are huge challenges. At newly formed Juno Therapeutics, they have a plan to overcome these obstacles--find a CEO who has done it before and back him with $120 million.
The environment that exists inside a person's intestines may impact the effectiveness of cancer therapy, according to new research by investigators at the National Cancer Institute and France's Gustave Roussy Institute.
Lately, there's been a lot of scrutiny surrounding preclinical research. Last year, a former researcher at Amgen ($AMGN) found that many basic cancer studies--published in leading science...
A compound derived from vegetables such as cabbage, cauliflower and broccoli may be able to protect cancer patients against the unpleasant and harmful effects of radiation therapy, according to a new study.
So just what is Google up to? All we know for sure right now is that CEO Larry Page has expressed some rather vague but gigantic goals for the newly created company Calico, such as significantly adding on to the expected lifespan for humans while tackling health issues related to aging.
AstraZeneca is rolling the dice on a $500 million deal--including $225 million upfront--to buy the early-stage cancer immunology specialist Amplimmune for its U.S. biologics arm MedImmune. AstraZeneca is promising up to $275 million in development milestones.
Shares of Memphis-based GTx were eviscerated this morning after the biotech reported that a pair of Phase III studies of a muscle drug for cancer patients had failed.
U.K. researchers have discovered what role a newly identified team of proteins play in the process of cell division, and they say that harnessing these proteins could provide a new way to kill cancerous cells.
A DNA cancer vaccine developed by Blue Bell, PA-based Inovio Pharmaceuticals caused tumor cell death and increased the rate of survival in animal studies.
Bernard Munos, one of the sharpest critics of the drug development industry, takes Big Pharma to task once again on the innovation front after reviewing just what's been approved over the past 12 years.